CTNNB1 and acute myeloid leukemia: With somestudies identifying GPR84 as a new regulator of Catenin beta-1 (β-catenin) thatcould potentially be a therapy target for AML patients.40 However, theexact mechanisms and roles of GPR84 in AML development remains unclear.